Catherine Hall, VP Product Strategy at endpoint Clinical tells the story of the past of Direct-to-Patient Distribution and speculates on the future at Direct-to-Patient and Virtual Clinical Trials 2020. Learning from the evolution of technology and trial design to address the barriers of Direct-to-Patient and how COVID-19 is reshaping the future of decentralized trials.
What you’ll learn:
- Why DTP models have been slow to adopt
- How the evolution of trial design has helped to evolve technology and vice versa
- How COVID-19 has enhanced collaboration
- How the total eco-system will continue to evolve
Contact us to discuss this topic further, and connect with our thought leader, Catherine Hall, on LinkedIn.
Catherine Hall, VP of Product Strategy, endpoint Clinical
Cat Hall started her career as an academic scientist in Molecular and Cellular Biology before finishing her MBA and transitioning into Pharmaceutical Supply Chain Management. During her career, she developed notable expertise not only in clinical supplies but also in training development, process improvement, managing partnerships, and the design and implementation of technologies such as Interactive Response Technology (IRT). She is well-known for focusing on bridging the GMP/GCP gap by bringing supply chain customer service through the last mile to patients. Cat joined endpoint in 2019 as VP of Product Strategy to help continue to bring the customer voice forward into shaping the future of IRT.